From October 1, 2023 to December 20, 2023, the company has repurchased 244,200 shares, representing 0.23% for CNY 15.94 million. With this, the company has completed the repurchase of 777,300 shares, representing 0.72% for CNY 49.99 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
67.46 CNY | -5.12% | -2.03% | +3.63% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.63% | 1.01B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.